相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Dual mTORC1/2 Blockade Inhibits Glioblastoma Brain Tumor Initiating Cells In Vitro and In Vivo and Synergizes with Temozolomide to Increase Orthotopic Xenograft Survival
H. Artee Luchman et al.
CLINICAL CANCER RESEARCH (2014)
Randomized Phase III Trial of Temsirolimus Versus Sorafenib As Second-Line Therapy After Sunitinib in Patients With Metastatic Renal Cell Carcinoma
Thomas E. Hutson et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
A prospective evaluation of VEGF-targeted treatment cessation in metastatic clear cell renal cancer
T. Powles et al.
ANNALS OF ONCOLOGY (2013)
Combined Inhibition of mTORC1 and mTORC2 Signaling Pathways Is a Promising Therapeutic Option in Inhibiting Pheochromocytoma Tumor Growth: In Vitro and In Vivo Studies in Female Athymic Nude Mice
Alessio Giubellino et al.
ENDOCRINOLOGY (2013)
Evolutionarily conserved regulation of TOR signalling
Terunao Takahara et al.
JOURNAL OF BIOCHEMISTRY (2013)
A Comparison of Ku0063794, a Dual mTORC1 and mTORC2 Inhibitor, and Temsirolimus in Preclinical Renal Cell Carcinoma Models
Hao Zhang et al.
PLOS ONE (2013)
Investigational drug MLN0128, a novel TORC1/2 inhibitor, demonstrates potent oral antitumor activity in human breast cancer xenograft models
Yesim Goekmen-Polar et al.
BREAST CANCER RESEARCH AND TREATMENT (2012)
mTOR Signaling in Growth Control and Disease
Mathieu Laplante et al.
CELL (2012)
Rapid Angiogenesis Onset after Discontinuation of Sunitinib Treatment of Renal Cell Carcinoma Patients
Arjan W. Griffioen et al.
CLINICAL CANCER RESEARCH (2012)
Axl is essential for VEGF-A-dependent activation of PI3K/Akt
Guo-Xiang Ruan et al.
EMBO JOURNAL (2012)
Focal adhesion kinase regulation of neovascularization
Kishore K. Wary et al.
MICROVASCULAR RESEARCH (2012)
Longitudinal Imaging Studies of Tumor Microenvironment in Mice Treated with the mTOR Inhibitor Rapamycin
Keita Saito et al.
PLOS ONE (2012)
AKT Inhibition Relieves Feedback Suppression of Receptor Tyrosine Kinase Expression and Activity
Sarat Chandarlapaty et al.
CANCER CELL (2011)
Reciprocal Feedback Regulation of PI3K and Androgen Receptor Signaling in PTEN-Deficient Prostate Cancer
Brett S. Carver et al.
CANCER CELL (2011)
Reduced VEGF Production, Angiogenesis, and Vascular Regrowth Contribute to the Antitumor Properties of Dual mTORC1/mTORC2 Inhibitors
Beverly L. Falcon et al.
CANCER RESEARCH (2011)
Sequential use of targeted agents in the treatment of renal cell carcinoma
Thomas E. Hutson et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2011)
Rapamycin passes the torch: a new generation of mTOR inhibitors
Don Benjamin et al.
NATURE REVIEWS DRUG DISCOVERY (2011)
mTOR Kinase Inhibition Causes Feedback-Dependent Biphasic Regulation of AKT Signaling
Vanessa S. Rodrik-Outmezguine et al.
CANCER DISCOVERY (2011)
Phase 3 Trial of Everolimus for Metastatic Renal Cell Carcinoma Final Results and Analysis of Prognostic Factors
Robert J. Motzer et al.
CANCER (2010)
AZD8055 Is a Potent, Selective, and Orally Bioavailable ATP-Competitive Mammalian Target of Rapamycin Kinase Inhibitor with In vitro and In vivo Antitumor Activity
Christine M. Chresta et al.
CANCER RESEARCH (2010)
Rapamycin Inhibition of the Akt/mTOR Pathway Blocks Select Stages of VEGF-A164-Driven Angiogenesis, in Part by Blocking S6Kinase
Qi Xue et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2009)
Ku-0063794 is a specific inhibitor of the mammalian target of rapamycin (mTOR)
Juan M. Garcia-Martinez et al.
BIOCHEMICAL JOURNAL (2009)
Targeted Inhibition of Mammalian Target of Rapamycin for the Treatment of Advanced Renal Cell Carcinoma
Anil Kapoor et al.
CANCER (2009)
Accelerated Metastasis after Short-Term Treatment with a Potent Inhibitor of Tumor Angiogenesis
John M. L. Ebos et al.
CANCER CELL (2009)
mTOR Inhibitor RAD001 (Everolimus) Has Antiangiogenic/Vascular Properties Distinct from a VEGFR Tyrosine Kinase Inhibitor
Heidi A. Lane et al.
CLINICAL CANCER RESEARCH (2009)
Active-Site Inhibitors of mTOR Target Rapamycin-Resistant Outputs of mTORC1 and mTORC2
Morris E. Feldman et al.
PLOS BIOLOGY (2009)
Reversible tumor growth acceleration following bevacizumab interruption in metastatic colorectal cancer patients scheduled for surgery
W. Cacheux et al.
ANNALS OF ONCOLOGY (2008)
Rictor and integrin-linked kinase interact and regulate Akt phosphorylation and cancer cell survival
Paul C. McDonald et al.
CANCER RESEARCH (2008)
Molecular origins of cancer: Tumor angiogenesis
Robert S. Kerbel
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Src-mediated phosphorylation of hsp90 in response to vascular endothelial growth factor (VEGF) is required for VEGF receptor-2 signaling to endothelial NO synthase
Martine Duval et al.
MOLECULAR BIOLOGY OF THE CELL (2007)
Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma
Gary Hudes et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Ablation in mice of the mTORC components raptor, rictor, or mLST8 reveals that mTORC2 is required for signaling to Akt-FOXO and PKCα but not S6K1
David A. Guertin et al.
DEVELOPMENTAL CELL (2006)
Pathological angiogenesis is induced by sustained Akt signaling and inhibited by rapamycin
Thuy L. Phung et al.
CANCER CELL (2006)
Antianglogenic potential of the mammalian target of rapamycin inhibitor temsirolimus
Donatella Del Bufalo et al.
CANCER RESEARCH (2006)
mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt
KE O'Reilly et al.
CANCER RESEARCH (2006)
Regulation of vascular endothelial growth factor receptor 2-mediated phosphorylation of focal adhesion kinase by heat shock protein 90 and Src kinase activities
F Le Boeuf et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton
DD Sarbassov et al.
CURRENT BIOLOGY (2004)
Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive
E Jacinto et al.
NATURE CELL BIOLOGY (2004)
MTOR interacts with Raptor to form a nutrient-sensitive complex that signals to the cell growth machinery
DH Kim et al.
CELL (2002)
Src-mediated coupling of focal adhesion kinase to integrin αvβ5 in vascular endothelial growth factor signaling
BP Eliceiri et al.
JOURNAL OF CELL BIOLOGY (2002)
Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor
M Guba et al.
NATURE MEDICINE (2002)
分享论文
